MiMedx Group, Inc. (MDXG) Key Metrics
MDXG valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $646.5M
- Enterprise value
- $578.2M
- P/E (TTM)
- 110.8 10-yr median 22.6
- Forward P/E
- 19.5
- PEG ratio
- 2.88
- Price / sales
- 1.8 10-yr median 3.4
- Price / book
- 3.2 10-yr median 7.5
- EV / EBITDA
- 28.3 10-yr median 30.8
- Dividend yield
- —
- Beta
- 1.17
MDXG key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMDXG valuation Price multiples at each fiscal year-end price.
MDXG returns How much profit the business earns on the capital it uses.
MDXG per-share figures Results divided by the shares outstanding at year-end.
MDXG financial health Debt, liquidity and how easily interest is covered.
MDXG efficiency & capital use Working capital cycle and where the cash goes.
MDXG valuation history
MDXG returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MDXG debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MDXG cash returned to shareholders
MDXG price vs earnings per share
MDXG key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.01B | $1.43B | $1.28B | $313.9M | $666.5M | $983.0M | $800.4M | $195.3M | $1.46B | $998.0M |
| Enterprise value | $870.0M | $1.35B | $1.25B | $300.4M | $632.7M | $939.0M | $755.5M | $150.2M | $1.44B | $963.7M |
| P/E ratio | 20.9 | 33.8 | 19.0 | — | — | — | — | — | 22.6 | 83.4 |
| Price / sales | 2.4 | 4.1 | 4.0 | 1.2 | 2.8 | 4.0 | 2.2 | 0.5 | 4.6 | 4.1 |
| Price / book | 4.0 | 7.4 | 9.0 | 4.2 | 7.2 | 10.8 | 16.1 | 3.9 | 19.8 | 7.5 |
| Price / free cash flow | 13.9 | 22.2 | 51.6 | — | — | — | 30.3 | 7.6 | 25.3 | 56.6 |
| Price / operating cash flow | 13.7 | 21.7 | 47.8 | — | — | — | 22.4 | 5.5 | 23.3 | 41.8 |
| EV / sales | 2.1 | 3.9 | 3.9 | 1.1 | 2.6 | 3.8 | 2.1 | 0.4 | 4.5 | 3.9 |
| EV / EBITDA | 10.5 | 20.7 | 30.8 | — | — | — | 42.9 | 50.2 | 27.3 | 108.0 |
| EV / free cash flow | 11.9 | 21.0 | 50.3 | — | — | — | 28.6 | 5.8 | 24.9 | 54.6 |
| Earnings yield | 4.8% | 3.0% | 5.3% | −9.6% | −1.8% | −5.0% | −3.7% | −15.4% | 4.4% | 1.2% |
| Free cash flow yield | 7.2% | 4.5% | 1.9% | −6.6% | −0.8% | −4.2% | 3.3% | 13.2% | 3.9% | 1.8% |
| Dividend yield | — | — | 0.1% | 0.2% | 0.2% | 10.2% | — | — | — | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.3% | 0.2% | 0.8% | 0.6% | 0.9% | 10.3% | 1.6% | 2.1% | 4.9% | 1.2% |
| Share price at fiscal year-end | $6.77 | $9.62 | $8.77 | $2.78 | $6.04 | $9.08 | $7.58 | $1.79 | $12.61 | $8.86 |
| Per share | ||||||||||
| Revenue per share | $2.80 | $2.34 | $2.20 | $2.37 | $2.19 | $2.29 | $3.40 | $3.29 | $2.77 | $2.18 |
| Earnings per share | $0.32 | $0.28 | $0.46 | −$0.27 | −$0.11 | −$0.46 | −$0.28 | −$0.27 | $0.56 | $0.11 |
| Operating cash flow per share | $0.49 | $0.44 | $0.18 | −$0.16 | −$0.02 | −$0.36 | $0.34 | $0.33 | $0.54 | $0.21 |
| Free cash flow per share | $0.49 | $0.43 | $0.17 | −$0.18 | −$0.05 | −$0.38 | $0.25 | $0.24 | $0.50 | $0.16 |
| Cash per share | $1.11 | $0.70 | $0.56 | $0.58 | $0.79 | $0.89 | $0.43 | $0.41 | $0.24 | $0.31 |
| Book value per share | $1.71 | $1.30 | $0.98 | $0.66 | $0.84 | $0.84 | $0.47 | $0.46 | $0.64 | $1.18 |
| Tangible book value per share | $1.49 | $1.09 | $0.81 | $0.44 | $0.61 | $0.60 | $0.19 | $0.18 | $0.38 | $0.79 |
| Dividends per share | — | — | $0.01 | $0.01 | $0.01 | $0.92 | — | — | — | $0.00 |
| Capex per share | $0.01 | $0.01 | $0.01 | $0.02 | $0.03 | $0.02 | $0.09 | $0.09 | $0.04 | $0.06 |
| Debt per share | $0.15 | $0.17 | $0.33 | $0.46 | $0.48 | $0.48 | $0.00 | — | $0.00 | $0.00 |
| Shares outstanding | 149.7M | 149.0M | 146.0M | 112.9M | 110.4M | 108.3M | 105.6M | 109.1M | 116.1M | 112.6M |
| Change in shares outstanding | +0.5% | +2.1% | +29.3% | +2.3% | +1.9% | +2.5% | −3.2% | −6.0% | +3.1% | −0.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 21.6% | 25.3% | 62.1% | −36.1% | −13.4% | −69.9% | −60.4% | −48.6% | 62.6% | 9.9% |
| Return on invested capital (ROIC) | 41.4% | 38.8% | 43.7% | −19.4% | −10.5% | −137.4% | −66.6% | −12.1% | 63.6% | 0.5% |
| Return on assets (ROA) | 16.0% | 16.9% | 32.9% | −16.8% | −6.3% | −30.3% | −24.4% | −24.6% | 41.2% | 7.3% |
| Return on tangible assets | 15.7% | 18.2% | 31.5% | −20.7% | −7.6% | −28.0% | −32.1% | −32.1% | 70.9% | 8.0% |
| Free cash flow margin | 17.4% | 18.5% | 7.7% | −7.7% | −2.1% | −16.8% | 7.3% | 7.2% | 18.0% | 7.2% |
| Income quality (OCF / net income) | 1.52 | 1.56 | 0.40 | — | — | — | — | — | 0.97 | 1.99 |
| Financial health | ||||||||||
| Total debt | $22.5M | $24.8M | $48.1M | $52.5M | $53.3M | $51.8M | $229,000 | — | $286,000 | $31,000 |
| Cash & short-term investments | $166.1M | $104.4M | $82.0M | $66.0M | $87.1M | $95.8M | $45.1M | $45.1M | $27.5M | $34.4M |
| Net debt | −$143.6M | −$79.6M | −$33.9M | −$13.5M | −$33.8M | −$44.0M | −$44.9M | −$45.1M | −$27.2M | −$34.4M |
| Debt / equity | 0.09 | 0.13 | 0.34 | 0.70 | 0.58 | 0.57 | 0.00 | — | 0.00 | 0.00 |
| Debt / assets | 0.07 | 0.09 | 0.20 | 0.31 | 0.28 | 0.26 | 0.00 | — | 0.00 | 0.00 |
| Net debt / EBITDA | −1.73 | −1.22 | −0.84 | — | — | — | −2.55 | −15.08 | −0.52 | −3.85 |
| Current ratio | 4.32 | 4.21 | 3.57 | 3.08 | 3.51 | 2.71 | 1.03 | 1.03 | 1.06 | 2.49 |
| Quick ratio | 3.92 | 3.69 | 3.11 | 2.78 | 3.24 | 2.54 | 0.81 | 0.81 | 0.86 | 2.14 |
| Interest coverage | 35.8 | 58.5 | 5.7 | -2.9 | -1.4 | -5.7 | — | — | 531.3 | 2.6 |
| Working capital | $213.2M | $146.3M | $118.3M | $90.6M | $106.2M | $101.5M | $2.5M | $2.5M | $2.9M | $75.8M |
| Invested capital | $113.0M | $113.5M | $108.8M | $61.0M | $58.8M | $47.4M | $4.8M | $4.5M | $46.6M | $98.6M |
| Tangible asset value | $222.9M | $162.0M | $118.0M | $49.2M | $67.2M | $65.4M | $20.1M | $20.1M | $43.8M | $89.5M |
| Net current asset value | $191.4M | $121.1M | $67.9M | $37.3M | $53.2M | $50.0M | $860,000 | $860,000 | $1.3M | $66.3M |
| Graham number | $3.54 | $2.88 | $3.19 | — | — | — | — | — | $2.82 | $1.68 |
| Graham net-net per share | $1.00 | $0.59 | $0.25 | $0.07 | $0.25 | $0.16 | −$0.19 | −$0.18 | −$0.13 | $0.30 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $997,000 | $651,000 | $1.4M | $100.0M | — | — | — | $0 |
| Share buybacks (net) | $3.1M | $2.6M | $9.5M | $1.2M | $4.8M | $1.5M | $12.5M | $4.0M | $72.3M | $11.5M |
| Dividend payout ratio | — | — | 1.5% | — | — | — | — | — | — | 0.0% |
| Dividends + buybacks / free cash flow | 4.3% | 4.1% | 42.4% | — | — | — | 47.3% | 15.6% | 125.1% | 65.4% |
| Capex / revenue | 0.2% | 0.5% | 0.6% | 1.0% | 1.3% | 0.9% | 2.6% | 2.6% | 1.6% | 2.5% |
| Capex / operating cash flow | 1.4% | 2.5% | 7.4% | — | — | — | 26.3% | 26.3% | 8.1% | 26.0% |
| Capex / depreciation | 0.07 | 0.28 | 0.58 | 0.66 | 0.62 | 0.29 | 1.36 | 1.36 | 0.89 | 1.13 |
| Stock-based compensation / revenue | 3.9% | 4.9% | 5.3% | 4.7% | 5.8% | 4.9% | 4.1% | — | 6.6% | 7.2% |
| R&D / revenue | 3.6% | 3.5% | 3.9% | 4.7% | 4.1% | 4.7% | 4.4% | 4.4% | 5.6% | 5.9% |
| SG&A / revenue | 63.6% | 64.5% | 64.3% | 78.0% | 82.0% | 72.9% | 70.3% | 70.3% | 67.3% | 69.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 57.3 | 57.4 | 55.0 | 56.9 | 57.1 | 26.4 | 0.5 | 0.6 | 38.5 | 90.1 |
| Days of inventory on hand | 122.8 | 136.2 | 114.3 | 92.8 | 100.2 | 122.3 | 160.4 | 127.7 | 141.4 | 142.3 |
| Days payables outstanding | 54.8 | 50.0 | 58.5 | 59.8 | 74.4 | 109.6 | 149.1 | 117.0 | 103.1 | 101.8 |
| Cash conversion cycle (days) | 125.4 | 143.6 | 110.8 | 89.8 | 82.9 | 39.0 | 11.7 | 11.3 | 76.8 | 130.6 |
| Receivables turnover | 6.37 | 6.36 | 6.63 | 6.42 | 6.39 | 13.84 | 790.99 | 647.05 | 9.47 | 4.05 |
| Payables turnover | 6.66 | 7.30 | 6.24 | 6.10 | 4.91 | 3.33 | 2.45 | 3.12 | 3.54 | 3.59 |
| Inventory turnover | 2.97 | 2.68 | 3.19 | 3.93 | 3.64 | 2.99 | 2.28 | 2.86 | 2.58 | 2.56 |
| Asset turnover | 1.38 | 1.39 | 1.57 | 1.49 | 1.24 | 1.53 | 2.92 | 2.94 | 2.04 | 1.49 |
| Average receivables | $65.8M | $54.8M | $48.5M | $41.7M | $37.9M | $17.9M | $454,000 | $555,000 | $33.9M | $60.5M |
| Average payables | $11.0M | $8.2M | $8.8M | $7.9M | $8.1M | $11.8M | $14.9M | $11.7M | $9.9M | $9.0M |
| Average inventory | $24.6M | $22.4M | $17.1M | $12.3M | $10.9M | $13.2M | $16.0M | $12.7M | $13.6M | $12.6M |
| Intangibles / total assets | 9.8% | 11.8% | 10.3% | 14.8% | 13.5% | 12.9% | 24.1% | 24.1% | 24.7% | 22.5% |
Computed from MDXG's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MDXG valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), MiMedx traded at 20.9 times earnings, against a 10-year median of 22.6. Based on the latest twelve months, the trailing P/E is 110.8 and the forward P/E is 19.5. MiMedx earned a return on equity of 21.6% and a return on invested capital of 41.4% in fiscal 2025. It ended the year with $22.5 million of debt and $166.1 million in cash and short-term investments, a net cash position of $143.6 million. It returned $3.1 million to shareholders: $0 in dividends and $3.1 million in share buybacks, 4% of free cash flow. The share count rose 32.9% from 112.6M to 149.7M over 9 years.
See the MDXG income statement, the MDXG chart for price history, or the MDXG stock overview for the latest quote and news.
MDXG key metrics FAQ
What is MiMedx's P/E ratio?
MiMedx's trailing P/E ratio is 110.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 19.5. At the end of fiscal 2025 it was 20.9, compared with a 10-year median of 22.6.
What is MiMedx's EV/EBITDA?
MiMedx's enterprise value was 10.5 times EBITDA at the end of fiscal 2025 (enterprise value $870.0 million, EBITDA $82.9 million); the current EV/EBITDA is 28.3.
What is MiMedx's return on equity?
MiMedx's return on equity (ROE) was 21.6% in fiscal 2025: net income of $48.6 million on average shareholders' equity of $224.8 million.
What is MiMedx's ROIC?
MiMedx's return on invested capital was 41.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does MiMedx have?
MiMedx had total debt of $22.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
Does MiMedx buy back its shares?
Yes. MiMedx spent $3.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.5% over the year, to 149.7M..
What is MiMedx's free cash flow yield?
MiMedx generated $73.0 million of free cash flow in fiscal 2025, a free cash flow yield of 7.2% on its market value at year-end ($1.0 billion).
What is MiMedx's current ratio?
MiMedx's current ratio was 4.32 at the end of fiscal 2025: current assets were 4.32 times current liabilities.